ArticleInfection and drug resistance2025
In vitro Activity of Eravacycline and Risk Factors for Carbapenem-Resistant Acinetobacter Baumannii Infections in Patients with Respiratory Diseases: A Retrospective Cohort Study.
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbapenem-resistant Acinetobacter baumannii (CRAB) infections, particularly among respiratory patients, are associated with high mortality rates and substantial healthcare costs, exceeding $1.2 billion annually. Current the medications are recommended therapies, including Colistin and Tigecycline, face significant limitations, such as nephrotoxicity and inadequate lung tissue penetration. In contrast, Eravacycline (ERV), a novel fluorocycline, exhibits potent activity against multidrug-resistant Gram-negative pathogens and may help mitigate these limitations. Patients and Methods: A retrospective analysis was conducted on 1071 CRAB isolates obtained from 524 respiratory patients at Shaanxi Provincial People's Hospital in 2024. Bacterial identification was performed using mass spectrometry (Zhongyuan Co). while drug susceptibility testing was carried out using the BD Phoenix M50 (Becton Dickinson) and E-test strips (Liofilchem). Multivariable logistic regression was applied to identify independent risk factors, including age, intubation history, comorbidities, and the use of feeding tubes, with adjusted odds ratios (OR), 95% confidence intervals (CI), and P-values reported. Results: Tracheal intubation emerged as the strongest independent risk factor for CRAB acquisition (OR=3.325, 95% CI: 2.273-4.865, Conclusion: Endotracheal intubation significantly contributes to the transmission of CRAB, underscoring the necessity for employing early respiratory ventilation and ERV as a recommended therapies therapeutic strategy in environments with elevated β-lactam resistance. Serum amyloid A (SAA) and interleukin-6 (IL-6) are important prognostic biomarkers that facilitate risk stratification. The implementation of infection control measures that prioritize intubation-associated practices is essential for alleviating the burden of CRAB infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.